Topline data on schedule for summer 2020Systemic sclerosis (SSc) is a rare, serious and life-threatening autoimmune disease affecting ~200,000 people in the U.S., EU and.
These previously presented data demonstrated lenabasum improved efficacy outcomes and underlying disease pathology compared to placebo and had an acceptable safety profile in.
GAITHERSBURG, Md., April 30, 2020 -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today.
Q4 2019 Corbus Pharmaceuticals Holdings Inc Earnings Call
Q1 2020 Corbus Pharmaceuticals Holdings Inc Earnings Call
Topline results for lenabasum Phase 3 RESOLVE-1 study in systemic sclerosis remain on schedule for summer of 2020, followed by Phase 2b study data in cystic fibrosis Phase 1.
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking...
Dr. Salzmann brings 20 years of industry experience and currently serves as Chief Executive Officer of Immunovant (IMVT), a biopharmaceutical company focused on developing therapies for patients with autoimmune diseases. Prior to joining Immunovant, Dr. Salzmann held various leadership roles at Eli Lilly and Company, where he most recently served as Global Clinical Development Leader for baricitinib (Olumiant®).
Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
- Management to host conference call and webcast on Thursday, March 12 at 8:30 a.m. ET - Norwood, MA, March 05, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP).
There's been a notable change in appetite for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) shares in the week...
- Management to host conference call and webcast on Monday, May 11 at 8:30 a.m. ET- NORWOOD, MA, May 04, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”.
First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activationSecond abstract outlines baseline characteristics of.
Topline results for Phase 3 study in systemic sclerosis on schedule for summer of 2020 followed by Phase 2b study results in cystic fibrosis Completed $46 million public.
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March ...
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Norwood, MA, May 15, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering.